---
document_datetime: 2023-09-21 21:17:21
document_pages: 15
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zerbaxa-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zerbaxa-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.5428958
conversion_datetime: 2025-12-28 12:52:14.393632
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zerbaxa

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0036              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 23/06/2022                          | 25/07/2022                                  | SmPC and PL                      |           |
| WS/2193              | This was an application for a variation following a worksharing procedure according to Article 20 of                           | 02/06/2022                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | Commission Regulation (EC) No 1234/2008. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                               |            |            |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|
| PSUSA/10411 /202012 | Periodic Safety Update EU Single assessment - ceftolozane / tazobactam                                                                                                                                                                                                                                                                                                                       | 02/09/2021 | n/a        | PRAC Recommendation - maintenance |
| IAIN/0034           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                   | 15/02/2021 | 17/06/2021 | II and PL                         |
| II/0032             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                               | 03/12/2020 | 17/06/2021 | and PL                            |
| IA/0033             | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                  | 28/10/2020 | n/a        |                                   |
| PSUSA/10411 /202003 | Periodic Safety Update EU Single assessment - ceftolozane / tazobactam                                                                                                                                                                                                                                                                                                                       | 01/10/2020 | n/a        | PRAC Recommendation - maintenance |
| IB/0031/G           | This was an application for a group of variations. A.z - Administrative change - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or | 28/09/2020 | n/a        |                                   |

<div style=\"page-break-after: always\"></div>

|           | material/reagent/intermediate - Minor to an approved test procedure - Change in test procedure for the packaging of the AS - Minor changes to approved test procedure                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             | starting changes B.I.c.3.a immediate an   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------|
| IB/0030/G | This was an application for a group of variations. A.z - Administrative change - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or novel excipient                                                                                                                                                                                                                                    | 11/08/2020 | n/a        |             | manufacturer of a                         |
| IA/0029/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites | 07/07/2020 | n/a        |             |                                           |
| IB/0027   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/06/2020 | 17/06/2021 | SmPC and PL |                                           |

<div style=\"page-break-after: always\"></div>

|           | (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  |                                                                                                                                                                                                                                                                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0026    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 27/02/2020 | 17/04/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zerbaxa in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0025/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.c.3.a - Change in test procedure for the immediate packaging of the AS - Minor changes to an approved test procedure | 31/10/2019 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| IB/0024/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                                                                                                                                                                                                                                                                                                                                            | 31/10/2019 | n/a        |                                  |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| manufacturer of a novel B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.4.a - Change to applied during the manufacture Tightening of in-process B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.b.2.c - Change in starting material/reagent/intermediate changes to a test procedure   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | quality of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.c.3.a - Change in test procedure for the immediate packaging of the AS - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                      |            |            |             |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IB/0023             | B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                          | 09/10/2019 | n/a        |             |                                   |
| PSUSA/10411 /201903 | Periodic Safety Update EU Single assessment - ceftolozane / tazobactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 03/10/2019 | n/a        |             | PRAC Recommendation - maintenance |
| II/0020             | Extension of Indication to include treatment of Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) for Zerbaxa, based on results from the randomised, double-blind, multicentre clinical trial CXA-NP-11-04 (PN008). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance (sections 1, 2, 3, 4 and 6). The applicant also took the opportunity to implement editorial changes in sections in sections 5.2 of the | 25/07/2019 | 23/08/2019 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | SmPC and to bring Section 4.4 of the SmPC and section 2 of the PL in line with the latest Annex to the EC guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. Version 2.1 of the RMP was also submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                               |            |            |                 |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IA/0021/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 01/03/2019 | n/a        |                 |                                   |
| IA/0019             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                         | 27/11/2018 | 23/08/2019 | Annex II and PL |                                   |
| PSUSA/10411 /201803 | Periodic Safety Update EU Single assessment - ceftolozane / tazobactam                                                                                                                                                                                                                                                                                                                                                                                | 04/10/2018 | n/a        |                 | PRAC Recommendation - maintenance |
| II/0015/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                    | 05/07/2018 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the   |            |            |                        |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| T/0017 | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/05/2018 | 15/06/2018 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| PSUSA/10411 /201709   | Periodic Safety Update EU Single assessment - ceftolozane / tazobactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 12/04/2018   | n/a        |           | PRAC Recommendation - maintenance   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------|-------------------------------------|
| N/0016                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 06/03/2018   | 08/05/2018 | Labelling |                                     |
| IB/0014/G             | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 10/01/2018   | n/a        |           |                                     |

<div style=\"page-break-after: always\"></div>

| starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change in starting material/reagent/intermediate changes to an approved B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.III.2.b - Change to national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.z - Change in and/or limits of an AS, material/intermediate/reagent B.I.d.1.a.4 - Stability   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------|
| IB/0013/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor an approved test procedure | 10/01/2018 | n/a | changes to |

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall   |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10411 /201703 | Periodic Safety Update EU Single assessment - ceftolozane / tazobactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/09/2017 | n/a | PRAC Recommendation - maintenance |
| IA/0010             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 02/06/2017 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0009           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 02/06/2017   | 08/05/2018   | Annex II and PL   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------------|
| PSUSA/10411 /201609 | Periodic Safety Update EU Single assessment - ceftolozane / tazobactam                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 06/04/2017   | n/a          |                   | PRAC Recommendation - maintenance |
| IB/0008/G           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other | 24/02/2017   | n/a          |                   |                                   |

<div style=\"page-break-after: always\"></div>

|                     | or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                  |            |            |                 |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IB/0006/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.e.7.z. - Change in supplier of packaging components or devices (when mentioned in the dossier) - Other variation                                              | 02/12/2016 | n/a        |                 |                                   |
| PSUSA/10411 /201603 | Periodic Safety Update EU Single assessment - ceftolozane / tazobactam                                                                                                                                                                                                                                                                                                                       | 29/09/2016 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0005/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 15/09/2016 | 14/10/2016 | Annex II and PL |                                   |
| II/0003             | Update of sections 4.8 of the SmPC in order to include 'infusion site reactions' and ADRs with frequencies lower than 1% that have been associated with ceftolozane/tazobactam in line with                                                                                                                                                                                                  | 14/04/2016 | 14/10/2016 | SmPC and PL     |                                   |

<div style=\"page-break-after: always\"></div>

|           | the MAH's CCDS. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update section 5.1 of the SmPC to correct duplication of entry for the pathogen 'Enterobacter cloacae'. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IB/0002   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                        | 15/01/2016 | 14/10/2016 | SmPC and PL     |
| IAIN/0001 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                | 06/11/2015 | 14/10/2016 | Annex II and PL |